Bloomberg reported on 7 May that the pharmaceutical industry is mounting a fierce campaign against a new drug pricing proposal from President Donald Trump's administration. The plan, proposed as a potential method to help fund the president's tax cut agenda, could slash drug company revenues by as much as $1 trillion (£800bn) over the next decade.
[BACK TO NEWS]